As gene therapy developers progress through the clinical phases to commercial manufacture, additional capacity may be required resulting in the need to move to a new facility or invest in a build program. The DPS team has been designing these advanced facilities since the first gene therapy revolution in the late 1990s and brings many years of experience in the successful delivery of clinical and commercial facilities for our clients.

We understand our clients’ challenges in viral vector production and the evolving platforms for these highly complex molecules. We understand the challenges in building robust processes under tight schedules.

Let us share the best current strategies in flexible facilities, addressing rapid deployment needs while navigating the regulatory pathway to facility licensure. Contact us now to discuss your next gene therapy project.